Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Get Free Report) have been given an average rating of "Moderate Buy" by the eleven research firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $39.45.

TNDM has been the subject of several recent research reports. Stifel Nicolaus increased their price objective on Tandem Diabetes Care from $37.00 to $40.00 and gave the company a "buy" rating in a research note on Tuesday. Citigroup increased their target price on shares of Tandem Diabetes Care from $31.00 to $38.00 and gave the company a "neutral" rating in a research report on Wednesday, April 3rd. StockNews.com upgraded shares of Tandem Diabetes Care from a "sell" rating to a "hold" rating in a research report on Friday, April 19th. SVB Leerink upgraded shares of Tandem Diabetes Care from a "market perform" rating to an "outperform" rating and increased their price objective for the company from $34.00 to $45.00 in a report on Thursday. Finally, Leerink Partnrs upgraded Tandem Diabetes Care from a "market perform" rating to an "outperform" rating in a report on Thursday.

Tandem Diabetes Care Price Performance

Shares of TNDM stock traded down $0.32 on Friday, reaching $35.24. 783,779 shares of the company were exchanged, compared to its average volume of 1,721,603. Tandem Diabetes Care has a 1 year low of $13.82 and a 1 year high of $40.74. The company has a debt-to-equity ratio of 0.91, a quick ratio of 3.02 and a current ratio of 3.83. The business has a 50-day moving average price of $30.96 and a 200 day moving average price of $25.37. The company has a market cap of $2.28 billion, a price-to-earnings ratio of -10.24 and a beta of 1.12.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last posted its quarterly earnings data on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The firm had revenue of $196.80 million during the quarter, compared to analyst estimates of $204.86 million. Tandem Diabetes Care had a negative return on equity of 31.48% and a negative net margin of 29.77%. Equities research analysts forecast that Tandem Diabetes Care will post -1.62 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. MCF Advisors LLC increased its stake in Tandem Diabetes Care by 79.3% during the first quarter. MCF Advisors LLC now owns 1,006 shares of the medical device company's stock worth $36,000 after acquiring an additional 445 shares during the last quarter. Van ECK Associates Corp boosted its stake in Tandem Diabetes Care by 8.6% during the fourth quarter. Van ECK Associates Corp now owns 5,900 shares of the medical device company's stock worth $175,000 after buying an additional 467 shares during the period. Diversified Trust Co increased its position in shares of Tandem Diabetes Care by 5.6% during the fourth quarter. Diversified Trust Co now owns 10,573 shares of the medical device company's stock valued at $313,000 after acquiring an additional 564 shares during the last quarter. Raymond James & Associates raised its stake in shares of Tandem Diabetes Care by 1.9% in the 3rd quarter. Raymond James & Associates now owns 40,264 shares of the medical device company's stock valued at $836,000 after acquiring an additional 737 shares during the period. Finally, Commonwealth Equity Services LLC lifted its holdings in shares of Tandem Diabetes Care by 10.1% in the 3rd quarter. Commonwealth Equity Services LLC now owns 9,870 shares of the medical device company's stock worth $205,000 after acquiring an additional 908 shares during the last quarter.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.